Metformin is an inexpensive treatment that is often used for Type 2 diabetes to lower blood sugar levels by reducing glucose production in the liver. The drug is not regularly given to patients with Type 1 diabetes.
A clinical trial has revealed metformin can promote a patient's ability to repair their own damaged blood vessels by decreasing the presence of microRNAs (miRs) which increases the growth of blood vessels - in addition to improving glucose levels.
These microRNAs are messenger molecules which with regulate different genes in different cells.
Dr Jolanta Weaver, Senior Lecturer in Diabetes Medicine at Newcastle University and Honorary Consultant Diabetologist at Queen Elizabeth Hospital, Gateshead, led the clinical trial at the Gateshead hospital and is lead author of the work being published today in the International Journal of Molecular Sciences. She said: “This is an exciting development as understanding this underlying mechanism opens up the possibility of new forms of treatment which will lower the chances of patients with Type 1 diabetes developing heart disease.
“As the outcomes of heart disease are worse in diabetic patients compared to people who don’t have diabetes, there is a need to identify additional treatment options.
“Our previous study showed that the vascular stem cells were improved by metformin so this was the first example how metformin improved heart disease as well as lowering glucose levels.
“Now we know that the drug metformin was able to do this by lowering the presence of microRNAs.”
A previous study revealed the potential of metformin to slow the development or delay heart disease however, this is the first time that the potential of miRs in preventing heart disease have been identified.
The study – known as MERIT - was the first to test metformin for the cardioprotective effects in Type 1 diabetes patients. In an open label, case-controlled study, the treatment group consisted of 23 people, aged between 19 and 65, with Type 1 diabetes who were free of cardiovascular disease. They were treated with metformin for 8 weeks.
Patients in the treatment group were matched with a standard group of nine Type 1 diabetic patients taking standard insulin. Additionally, there were 23 participants in the "healthy" control group without diabetes.
At the start of the study, the anti-angiogenic microRNAs, miR-222, miR-195, and miR-21a were detected to be higher in type 1 diabetic patients compared to the control group. However, metformin treatment successfully reduced the levels of miR-222, miR-195, and miR-21a.
Moreover, as the levels of miR-222 lowered, there was a corresponding decrease in the amount of circulating endothelial cells, which indicates an improvement in vascular repair.
Dr Weaver adds: “These results confirm that as well as improving a patient’s blood sugar control, metformin is working to protect the heart.”
The team will now be working to further the work with the goal of developing new therapies based on regulating the levels of microRNAs.
REFERENCE: Elevated Anti-angiogenic miR-222, miR-195, and miR-21a in T1DM are Improved by Metformin Therapy, thus Elucidating Metformin Cardioprotective Effect; MERIT Study. Fahad W Ahmed, Sherin Bakhashab, Inda T Bastaman, Rachel E Crossland, Michael Glanville and Jolanta U Weaver. International Journal of Molecular Sciences.
The patient's perspective
Alex Laws was part of the Newcastle University clinical trial and is delighted with the progress in the study.
The 33-year-old, of Gateshead, was diagnosed with Type 1 diabetes when she was seven and has good control of her condition. She was enrolled on the clinical trial in the summer of 2013.
Alex said: "I previously worked in medical research so I know how important studies like this can be in helping people, like me, with Type 1 diabetes.
"Type 1 diabetes can lead to a number of complications, especially in the long-term, so it's important as much as possible is done to limit serious problems.
"Heart disease is a concern for people with Type 1 diabetes so understanding how treatments can help and improve the condition for patients is a good thing."
The North East Cluster for Healthy Ageing and Independent Living (NE-CHAIN) has won early-stage funding from UK Research and Innovation to cultivate the ageing market in Newcastle and the North East.
published on: 21 March 2019
This year’s Newcastle Poetry Festival programme will be launched this Thursday with performances by two of 2019’s most dynamic new poets.
published on: 20 March 2019